Lindus Health and Thirty Madison complete enrolment of personalised dermatology care pilot study

14^th December: Clinical trial company Lindus Health and Thirty Madison, a US-based family of specialised healthcare brands, have today announced the completion of enrolment of a trial to assess the effectiveness of their personalised dermatology telemedicine platform Facet.

The novel telehealth platform offers treatment to patients with various skin conditions, such as atopic dermatitis (eczema), through asynchronous evidence-based consultation, patient-reported monitoring and provider messaging. This involves using before and after photos as well as patient reports to monitor progress.

The announcement follows a study by the National Eczema Association in the U.S. revealing that almost 60% of eczema patients are interested in participating in a clinical trial for eczema, but fewer than 10% of patients have done so.

The trial of the Facet platform is being remotely run, with Lindus Health responsible for delivering the study, including data capture and management through their proprietary EDC, statistical analysis, and project management.

Neil Parikh, Chief Medical Officer of Thirty Madison, said:

“We are excited to continue to leverage Thirty Madison’s asynchronous telehealth platform to accelerate access to the care continuum - from specialists who support a patient’s clinical journey to a patient’s ability to participate in research studies that advance the treatment landscape. While this study was a small pilot, we are encouraged by the diversity of participants in the study - especially in the area of eczema - where we really need more diverse patient representation. 

Meri Beckwith, Co-Founder of Lindus Health, said:

“The Facet platform has the potential to expand treatment access to more eczema patients than ever before. It’s an example of the ground-breaking progress that healthtech companies can make to patient care in the coming years.

“We’re excited that our innovative clinical trial delivery service can help innovative companies like Thirty Madison bring the latest medical advancements to patients more quickly than the old-fashioned industry standard.”